Thymic Stromal Lymphopoietin Variation, Filaggrin Loss of Function, and the Persistence of Atopic Dermatitis

• Autores: David J. Margolis, Brian Kim, Andrea J. Apter, Jayanta Gupta, Ole Hoffstad
• Localización: JAMA Dermatology, ISSN 2168-6068, Vol. 150, Nº. 3, 2014, págs. 254-259
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Importance Atopic dermatitis (AD) is a common chronic illness of childhood.

    Objective To evaluate the association between thymic stromal lymphopoietin (TSLP) variation and the persistence of skin symptoms of AD.

    Design, Setting, and Participants A prospective cohort study was conducted in the general community. Participants included 796 children enrolled in the Pediatric Eczema Elective Registry.

    Exposure Evaluation of TSLP variation.

    Main Outcomes and Measures Self-reported outcome of whether a child�s skin had no symptoms of AD and required no medications for 6 months at 6-month intervals.

    Results We evaluated 14 variants of TSLP. The variant rs1898671 was significantly associated with the outcome in white children (P?=?.01). As measured by overlapping CIs, similar odds ratios (ORs) were noted among whites (OR, 1.72; 95% CI, 1.11-2.66) and African Americans (1.33; 0.52-3.45). Further within the subcohort of individuals with a filaggrin protein (FLG) loss-of-function mutation, those with TSLP variation were more likely to have less-persistent disease (OR, 4.92; 95% CI, 2.04-11.86).

    Conclusions and Relevance The TSLP variation is associated with less persistent AD. Therefore, TSLP may be a potential therapeutic target for the treatment of AD, especially in individuals with diminished barrier function due to FLG mutations. This is an attractive hypothesis that can be tested in clinical trials.

    .